Advanced bile acid-based multi-compartmental microencapsulated pancreatic β-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment

Artificial Cells, Nanomedicine and Biotechnology

Volumn 44, Issue 2, 2016, Pages 588-595

  Mooranian, Armin ^a   Negrulj, Rebecca ^a   Chen Tan, Nigel ^b   Fakhoury, Marc ^c   Arfuso, Frank ^a   Jones, Franca ^b   Al Salami, Hani ^a  

^a CURTIN UNIVERSITY   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Bile acid; Microencapsulation; Pancreatic beta cells; Seahorse analyzer

Indexed keywords

BODY FLUIDS; CYTOLOGY; MICROENCAPSULATION; POLYELECTROLYTES;

BILE ACID; BIOCHEMICAL ACTIVITY; BIOLOGICAL FUNCTIONS; FLUORESCENT COMPOUNDS; MITOCHONDRIAL RESPIRATION; PANCREATIC BETA CELLS; SEAHORSE ANALYZER; URSODEOXYCHOLIC ACID;

CELLS;

FLUORESCENT DYE; POLYELECTROLYTE; URSODEOXYCHOLIC ACID; MICROCAPSULE;

APOPTOSIS; ARTICLE; CELL COUNT; CELL DEATH; CELL HYPOXIA; CELL PROLIFERATION; CELL RESPIRATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG FORMULATION; DRUG STABILITY; ENERGY DISPERSIVE X RAY SPECTROSCOPY; ENERGY YIELD; HUMAN; HUMAN CELL; MICROCAPSULE; MICROENCAPSULATION; MICROSCOPY; MITOCHONDRIAL RESPIRATION; MTT ASSAY; OXIDATIVE PHOSPHORYLATION; PANCREAS ISLET BETA CELL; PARTICLE SIZE; RESPIRATORY CHAIN; ROENTGEN SPECTROSCOPY; SCANNING ELECTRON MICROSCOPY; SPINNING DISK CONFOCAL SCANNING MICROSCOPY; ZETA POTENTIAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; MECHANICS; MEDICINAL CHEMISTRY; METABOLISM; MITOCHONDRION; PATHOLOGY;

CAPSULES; CELL LINE; CELL RESPIRATION; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS; DRUG STABILITY; FLUORESCENT DYES; INSULIN-SECRETING CELLS; MECHANICAL PHENOMENA; MITOCHONDRIA; URSODEOXYCHOLIC ACID;

EID: 84959030910     PISSN: 21691401     EISSN: 2169141X     Source Type: Journal    
DOI: 10.3109/21691401.2014.971806     Document Type: Article

References (44)

1. Al-Salami H, Butt G, Tucker I, Fawcett PJ, Golocorbin-Kon S, Mikov I, Mikov M. 2009. Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 34:43-50.
2. Al-Salami H, Butt G, Tucker I, Golocorbin-Kon S, Mikov M. 2012. Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 37:99-108.
3. Al-Salami H, Butt G, Tucker I, Mikov M. 2008. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find Exp Clin Pharmacol. 30:107-113.
4. Al-Salami H, Kansara H, King J, Morar B, Jayathilaka B, Fawcett PJ, Mikov M. 2007. Bile acids: a bitter sweet remedy for diabetes. NZ Pharm J. 27:17-20.
5. Awasthi R, Kulkarni GT 2013. Development of novel gastroretentive drug delivery system of gliclazide: hollow beads. Drug Dev Ind Pharm. 1-11.
6. Barnett R. 2010. Historical keyword: diabetes. Lancet. 375:191.
7. Bonadonna RC, Cucinotta D, Fedele D, Riccardi G, Tiengo A. 2006. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care. 29: 2701-2707.
8. Brand M, Nicholls D. 2011. Assessing mitochondrial dysfunction in cells. Biochem J. 435:297-312.
9. Calasan J, Al-Salami H, Mikov M. 2012. Bile acids and probiotics could help treating diabetes. FEBS J. 279:267-267.
10. Chang TM. 1971. The in vivo effects of semipermeable microcapsules containing L-asparaginase on 6C3HED lymphosarcoma. Nature. 229:117-118.
11. Chang TM. 1992. Hybrid artificial cells: microencapsulation of living cells. ASAIO J. 38:128-130.
12. Chang TM, Johnson LJ, Ransome OJ 1967. Semipermeable aqueous microcapsules. IV. Nonthrombogenic microcapsules with heparin-complexed membranes. Can J Physiol Pharmacol. 45:705-715.
13. de Vos P., Faas MM, Strand B, Calafiore R. 2006. Alginate-based microcapsules for immunoisolation of pancreatic islets. Biomaterials. 27:5603-5617.
14. de Vos P., Hamel A, Tatarkiewicz K. 2002. Considerations for successful transplantation of encapsulated pancreatic islets. Diabetologia. 45:159-173.
15. Dranka BP, Hill BG, Darley-Usmar VM. 2010. Mitochondrial reserve capacity in endothelial cells: the impact of nitric oxide and reactive oxygen species. Free Radic Biol Med. 48:905-914.
16. Gerencser AA, Neilson A, Choi SW, Edman U, Yadava N, Oh RJ, et al 2009. Quantitative microplate-based respirometry with correction for oxygen diffusion. Anal Chem. 81:6868-6878.
17. Jiin WY. 2000. Development of new polycations for cell encapsulation with alginate. Mater Sci Eng. 1:59-63.
18. Kittel A, Falus A, Buzas E. 2013. Microencapsulation technology by nature: Cell derived extracellular vesicles with therapeutic potential. Eur J Microbiol Immunol (Bp). 3:91-96.
19. Kuhajda K, Kandrac J, Kevresan S, Mikov M, Fawcett JP 2006. Structure and origin of bile acids: an overview. Eur J Drug Metab Pharmacokinet. 31:135-143.
20. Lalic-Popovic M, Paunkovic J, Grujic Z, Golocorbin-Kon S, Al-Salami H, Mikov M. 2013a. Diabetes and hypertension increase the placental and transcellular permeation of the lipophilic drug diazepam in pregnant women. BMC Pregnancy Childbirth. 13:188.
21. Lalic-Popovic M, Vasovic V, Milijasevic B, Golocorbin-Kon S, Al-Salami H, Mikov M. 2013b. Deoxycholic acid as a modifier of the permeation of gliclazide through the blood brain barrier of a rat. J Diabetes Res. 2013:598603.
22. Maji D. 2004. Prevention of microvascular and macrovascular complications in diabetes mellitus. J Indian Med Assoc. 102:426, 428, 430 passim.
23. Malmgren S, Nicholls DG, Taneera J, Bacos K, Koeck T, Tamaddon A, et al 2009. Tight coupling between glucose and mitochondrial metabolism in clonal β-cells is required for robust insulin secretion. J Biol Chem. 284:32395-32404.
24. Martinez-Moya P, Romero-Calvo I, Requena P, Hernandez-Chirlaque C, Aranda CJ, Gonzalez R, et al 2013. Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis. Int Immunopharmacol. 15:372-380.
25. Mikov, M, Al-Salami H, Golocorbin-Kon G. 2012. Potentials and Limitations of Bile Acids and Probiotics in Diabetes Mellitus. pp. 365-402
26. Mikov M, Al-Salami H, Golocorbin-Kon S, Skrbic R, Raskovic A, Fawcett JP 2008. The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur J Drug Metab Pharmacokinet. 33:137-142.
27. Mooranian A, Negrulj R, Arfuso F, Al-Salami H. 2014a. Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β-cells. Artif Cells Nanomed Biotechnol. (Epub ahead of print).
28. Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, et al 2014b. Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics. J Pharm Innov. 9:150-157.
29. Negrulj R, Mooranian A., Al-Salami H. 2013. Potentials and Limitations of Bile Acids in Type 2 Diabetes Mellitus: Applications of Microencapsulation as a Novel Oral Delivery System. J Endocrinol Diabetes Mellitus. 1:49-59.
30. Nicholls DG, Darley-Usmar VM, Wu M, Jensen PB, Rogers GW, Ferrick DA 2010. Bioenergetic profile experiment using C2C12 myoblast cells. J Vis Exp. 46.
31. Pal D, Nayak AK 2012. Novel tamarind seed polysaccharide-alginate mucoadhesive microspheres for oral gliclazide delivery: in vitro-in vivo evaluation. Drug Deliv. 19:123-131.
32. Perez MJ, Briz O. 2009. Bile-acid-induced cell injury and protection. World J Gastroenterol. 15:1677-1689.
33. Puri S, Hebrok M. 2012. Diabetic beta Cells: To Be or Not To Be? Cell. 150:1103-4.
34. Rafaelsen OJ. 1964. Glycogen content of rat diaphragm after intraperitoneal injection of insulin and other hormones. Acta Physiol Scand. 61:314-322.
35. Sherman I, Fisher M. 1986. Hepatic transport of fluorescent molecules: in vivo studies using intravital TV microscopy. Hepatology. 6:444-449.
36. Steele JA, Halle JP, Poncelet D, Neufeld RJ 2013. Therapeutic cell encapsulation techniques and applications in diabetes. Adv Drug Deliv Rev.
37. Takka S, Cali AG 2012. Bile salt-reinforced alginate-chitosan beads. Pharm Dev Technol. 17:23-29.
38. Tuch BE, Hughes TC, Evans MD 2011. Encapsulated pancreatic progenitors derived from human embryonic stem cells as a therapy for insulin-dependent diabetes. Diabetes Metab Res Rev. 27:928-932.
39. Uludag H, Horvath V, Black JP, Sefton M V. 1994. Viability and protein secretion from human Hepatoma (HepG2) cells encapsulated in 400×μm polyacrylate microcapsules by submerged nozzle-liquid jet extrusion. Biotechnol Bioeng. 44:1199-1204.
40. Uludag H, Sefton MV 1990. Colorimetric assay for cellular activity in microcapsules. Biomaterials. 11:708-712.
41. Uludag H, Sefton M V. 1992. Metabolic activity of CHO fibroblasts in HEMA-MMA microcapsules. Biotechnol Bioeng. 39:672-678.
42. Whelehan M, Marison IW 2011. Microencapsulation using vibrating technology. J Microencapsul. 28:669-88.
43. Wikstrom JD, Sereda SB, Stiles L, Elorza A, Allister EM, Neilson A, et al 2012. A novel high-throughput assay for islet respiration reveals uncoupling of rodent and human islets. PLoS One. 7:e33023.
44. Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, Parslow D, et al 2007. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol. 292:C125-C136.